- Home
- STWD vs MDGL Comparison
STWD vs MDGL Comparison
Compare STWD & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STWD
- MDGL
- Stock Information
- Founded
- STWD 2009
- MDGL 2011
- Country
- STWD United States
- MDGL United States
- Employees
- STWD N/A
- MDGL N/A
- Industry
- STWD Real Estate Investment Trusts
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- STWD Real Estate
- MDGL Health Care
- Exchange
- STWD Nasdaq
- MDGL Nasdaq
- Market Cap
- STWD 6.7B
- MDGL 7.4B
- IPO Year
- STWD 2009
- MDGL N/A
- Fundamental
- Price
- STWD $19.85
- MDGL $306.08
- Analyst Decision
- STWD Buy
- MDGL Buy
- Analyst Count
- STWD 10
- MDGL 14
- Target Price
- STWD $22.44
- MDGL $347.33
- AVG Volume (30 Days)
- STWD 1.5M
- MDGL 319.4K
- Earning Date
- STWD 11-06-2024
- MDGL 10-31-2024
- Dividend Yield
- STWD 9.66%
- MDGL N/A
- EPS Growth
- STWD N/A
- MDGL N/A
- EPS
- STWD 1.18
- MDGL N/A
- Revenue
- STWD $436,461,000.00
- MDGL $76,813,000.00
- Revenue This Year
- STWD N/A
- MDGL N/A
- Revenue Next Year
- STWD N/A
- MDGL $194.49
- P/E Ratio
- STWD $16.81
- MDGL N/A
- Revenue Growth
- STWD 16.29
- MDGL N/A
- 52 Week Low
- STWD $18.43
- MDGL $168.25
- 52 Week High
- STWD $22.29
- MDGL $368.29
- Technical
- Relative Strength Index (RSI)
- STWD 44.72
- MDGL 48.76
- Support Level
- STWD $19.99
- MDGL $295.02
- Resistance Level
- STWD $20.38
- MDGL $324.24
- Average True Range (ATR)
- STWD 0.24
- MDGL 10.93
- MACD
- STWD -0.02
- MDGL -4.71
- Stochastic Oscillator
- STWD 4.76
- MDGL 26.70
About STWD STARWOOD PROPERTY TRUST INC. Starwood Property Trust Inc.
Starwood Property Trust Inc is an American real estate investment trust principally engaged in originating, acquiring, and managing commercial mortgage loans and commercial mortgage-backed securities in the U.S. and Europe. The company organizes its activities into Commercial and Residential Lending Segment, Infrastructure Lending Segment, Property Segment and Investing and Servicing Segment. The company generates the majority of its revenue from the Real estate commercial and residential lending segment, which is engaged in originating, acquiring, financing, and managing commercial first mortgages, and non-agency residential mortgages.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.